NasdaqGS - Nasdaq Real Time Price USD

Alumis Inc. (ALMS)

5.03
-0.29
(-5.45%)
At close: May 9 at 4:00:01 PM EDT
5.03
0.00
(0.00%)
After hours: May 9 at 7:57:35 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
Total Revenue
0
0
0
0
Operating Expense
300,754
300,754
158,174
113,850
Operating Income
-300,754
-300,754
-158,174
-113,850
Net Non Operating Interest Income Expense
12,020
12,020
3,368
1,992
Other Income Expense
-5,499
-5,499
-187
-72
Pretax Income
-294,233
-294,233
-154,993
-111,930
Net Income Common Stockholders
-294,233
-294,233
-154,993
-111,930
Diluted NI Available to Com Stockholders
-294,233
-294,233
-154,993
-111,930
Basic EPS
-10.38
--
-2.99
-2.91
Diluted EPS
-10.38
--
-2.99
-2.91
Basic Average Shares
28,341.87
--
51,844.73
38,410.62
Diluted Average Shares
28,341.87
--
51,844.73
38,410.62
Total Operating Income as Reported
-300,754
-300,754
-158,174
-113,850
Total Expenses
300,754
300,754
158,174
113,850
Net Income from Continuing & Discontinued Operation
-294,233
-294,233
-154,993
-111,930
Normalized Income
-288,827
-288,827
-154,874
-111,930
Interest Income
12,020
12,020
3,368
1,992
Net Interest Income
12,020
12,020
3,368
1,992
EBIT
-300,754
-300,754
-158,174
-113,850
EBITDA
-297,602
-297,602
-156,890
-113,600
Reconciled Depreciation
3,152
3,152
1,284
250
Net Income from Continuing Operation Net Minority Interest
-294,233
-294,233
-154,993
-111,930
Total Unusual Items Excluding Goodwill
-5,406
-5,406
-119
--
Total Unusual Items
-5,406
-5,406
-119
--
Normalized EBITDA
-292,196
-292,196
-156,771
-113,600
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
12/31/2022 - 6/28/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SLRN Acelyrin, Inc.
2.3600
-4.07%
 
NKGN NKGen Biotech, Inc.
0.1711
+3.70%
 
ARTV Artiva Biotherapeutics, Inc.
2.0800
-4.59%
 
MBX MBX Biosciences, Inc.
11.11
-5.12%
 
CRVS Corvus Pharmaceuticals, Inc.
4.4300
+32.24%
 
ADVM Adverum Biotechnologies, Inc.
2.8100
-9.94%
 
ZBIO Zenas BioPharma, Inc.
9.05
-2.58%
 
RZLT Rezolute, Inc.
3.7000
-0.54%
 
NTHI NeOnc Technologies Holdings, Inc.
7.34
+11.21%
 
KYTX Kyverna Therapeutics, Inc.
2.1100
-0.94%